Clinical Trial Update: Monosialoganglioside Ganglioside in Cerebral Radiation Necrosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating monosialoganglioside GM-1 for cerebral radiation necrosis is registered (sponsor: Zhejiang Cancer Hospital); current status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Radiation Necrosis

Drugs mentioned

• Monosialoganglioside GM-1 (monosialoganglioside GM-1)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Cerebral Radiation Necrosis | Phase 2 | Status: UNKNOWN